ClinicalTrials.gg
RecruitingNCT07569419MODELUpdated May 6, 2026

Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

An Early Phase 1 interventional study of Linaclotide 290 micrograms and Lactose placebo pill in Cystic Fibrosis (CF), sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Nottingham · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.

Planned enrollment
130th of 186
26 · median 69
Started
2026
with 7 others
Phase 1
25 of 236
1 open now
Primary completion
2026-08
later than 12 of 31 live
Registered
228th of 236
by date
Lead sponsor
5 of 236
University of Nottingham

Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 130th largest by planned enrollment of the 186 interventional ones that give a count, is one of 8 that started in 2026, is one of 25 in phase 1, reaches primary completion later than 12 of the 31 other live ones, and was the 228th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Cystic Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Linaclotide is a medicine used to treat constipation and irritable bowel syndrome with constipation (IBS-C). It works by acting on the surface of the gut lining, where it increases the movement of salt and water into the bowel. This softens stools, makes them easier to pass, and can also reduce gut pain

One advantage of linaclotide is that, unlike some natural substances in the gut, it is stable and can act throughout the intestine. Studies in animals show that it has the strongest effect in the upper small intestine, but it may act in other parts of the bowel as well. In people, however, it is not yet clear whether linaclotide mainly works in the small intestine or in the large intestine (colon). Knowing this is important, because it could help the investigators understand whether linaclotide might also be useful in other conditions, such as cystic fibrosis, where the gut does not handle fluid properly.

Linaclotide is taken as a capsule, but less than 1% is absorbed into the bloodstream. Instead, it stays in the gut, where it is broken down into smaller active parts. This means both the small intestine and colon may be exposed to its effects.

Until now, it has been hard to study this because traditional methods only measure one part of the gut at a time. A team at the University of Nottingham has developed MRI scanning methods that can safely and non-invasively measure water content in the small intestine and colon.

The aim of this pilot study is to use MRI in healthy volunteers to see exactly where linaclotide acts. This knowledge will help optimise future studies in conditions such as cystic fibrosis.

Read the detailed description

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. In CF, defective CFTR may lead to various clinical effects on the gastrointestinal (GI) system; indeed, many CF patients report significant GI symptoms, with the most frequent being attributable to the lower GI tract, including bloating, flatulence, abdominal pain, and borborygmi. Moreover, constipation is another prevalent GI symptom in CF patients. It is estimated that 10-57% of CF patients report constipation symptoms, with an even higher prevalence (approximately 73%) in adults over the age of 30. Symptoms such as constipation are hypothesised to occur due to decreased luminal fluid content resulting from a reduction in anion flow, which ultimately leads to increased amounts of viscous mucus and slowed transit of intestinal contents. Presently, these GI symptoms in CF patients are often treated with laxatives and enemas, and in some cases surgical treatment, which can be uncomfortable and invasive, suggesting that alternative treatments are required.

Linaclotide, a drug approved for safe use across Europe and in the UK, is a synthetic analogue of uroguanylin that activates guanylate cyclase-C (GC-C) receptors located on the luminal surface of intestinal epithelial cells. Activation of GC-C increases intracellular cyclic guanosine monophosphate (cGMP), which stimulates cGMP-dependent protein kinase II (PKGII) and protein kinase A (PKA). Collectively, these kinases activate CFTR, leading to chloride and water secretion into the intestinal lumen. In parallel, elevated cGMP inhibits the sodium-hydrogen exchanger 3 (NHE3), thereby reducing sodium and water absorption. Together, these actions promote fluid secretion and accelerate intestinal transit, leading to linaclotide being commonly prescribed for the treatment of chronic idiopathic constipation and irritable bowel syndrome with chronic constipation (IBS-C).

Meta-analyses confirm linaclotide's clinical benefit in chronic idiopathic constipation and IBS-C; however, its role in CF remains uncertain, though anecdotal reports and animal models suggest therapeutic potential. Linaclotide has less than 1% systemic bioavailability and is degraded in the upper small bowel by carboxypeptidases to an active metabolite, with a small proportion of the administered dose recovered in stool, providing exposure throughout the small and large intestine. However, the primary site of action in humans remains undefined.

Traditional perfusion methods provide only segmental information, limiting assessment of the whole intestine. By contrast, magnetic resonance imaging (MRI) enables non-invasive evaluation of gastrointestinal water content across multiple regions. The Nottingham group has validated MRI techniques for quantifying small bowel water content and assessing colonic chyme hydration via T1 mapping. These methods have been successfully applied to study the effects of various pharmacological agents on gastrointestinal function.

Aim: To define the site of action of linaclotide in healthy volunteers using MRI. Identifying the regional effects of linaclotide will help optimise its future evaluation in CF patients. Based on clinical observations in constipation, stool effects emerge within seven days; however, the investigators hypothesise that small bowel changes occur within 1-2 hours of dosing. Therefore, a one-day pre-dosing regimen is expected to elicit a measurable effect on both the small bowel and colon while minimising participant burden.

Subjects will take 290ug linaclotide /placebo on the day prior to study day (day -1) and on the study day

03

Conditions studied

  • Cystic Fibrosis (CF)

Browse trials for

Keywords

  • linaclotide
  • cystic fibrosis
  • gastrointestinal
  • MRI
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participant is willing and able to give for participation in the study

Not currently taking any medications (except for selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral pill).

Aged between 18-60 years.

Ability to conform to the study protocol, including overnight fasting, dietary and lifestyle restriction, administering linaclotide and placebo intervention, MRI scanning, consuming the rice pudding/blue dye meal, and rating stool frequency and appearance.

Exclusion criteria

Exclusion Criteria:

to MRI scanning (i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, unable to lie flat and relatively still for less than 5 minutes.)

Pregnancy, lactating, or planning pregnancy during the investigation declared by candidate.

History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function.

Reported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix).

Intestinal stoma.

Any medical condition that may potentially compromise participation in the study e.g., known food intolerance to rice pudding, known contraindication to the oral administration of linaclotide or placebo.

Has a (BMI) value less than 18.5 or greater than 35.

Will not agree to follow dietary and lifestyle restrictions required.

Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study.

Participants who are currently (or in the past 3 months) taking antibiotics or probiotics as these may impact GI function.

Participation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM.

Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse.

Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

-

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Linaclotide

    290 mcg linaclotide across 2 days

    Drug: Linaclotide 290 micrograms

  • Placebo comparator
    Placebo

    Lactose placebo

    Drug: Lactose placebo pill

Interventions

  • DrugLinaclotideStudies of LinaclotideLinaclotide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    290 mcg, 2 days dosing, oral capsule form

  • DrugLactose placebo pill

    Placebo form, oral capsules identical to linaclotide

06

What researchers measure

Primary outcomes

  1. Small bowel water content

    Area under curve (AUC) 0-360 minutes Water content in small bowel as assessed by MRI (mL)

    Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose

Secondary outcomes

  1. Colon water content

    Area under curve (AUC) 0-360 min Water content in the ascending colonic region as assessed by MRI (mL)

    Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose

  2. Colonic regional segmental volumes

    Total volume of regional colonic segments (ascending, transverse, descending, sigmorectal) as assessed by MRI (mL) at each time point.

    Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose

  3. Changes in stool consistency

    Stool consistency rated using Bristol stool scale (type 1-7; 7 being watery stool).

    Time frame: 2 days before intervention, 5 days post-intervention

  4. Changes in whole gut transit time (WGTT)

    Assessed by time to stool discolouration following administration of blue dye paste.

    Time frame: 1 day post-intervention

  5. Gastrointestinal symptom rating

    Assessing the severity of common gastrointestinal symptoms (flatulence / gas passage, diarrhoea / loose stool, bloating, abdominal pain) via Likert-type scale: 0 = not at all 1. = mild (distinct but negligible) 2. = moderate (annoying) 3. = severe (disabling

    Time frame: 2 days pre-intervention and 5 days post-intervention

  6. Changes in stool frequency

    Frequency (per day) of bowel movements (number with exact time)

    Time frame: 2 days before starting intervention and for 5 days post intervention

  7. Small bowel motility

    Maximum motility score (A.U) of the small bowel as assessed by MRI

    Time frame: Baseline, and 0, 60, 120, 180, 240, 300, 360 minutes post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wilkinson-Smith, V., Hoad, C., Atkinson, D., Marciani, L., Corsetti, M., Scott, S. M., Taylor, S., Gowland, P., & Spiller, R. (2021). O59 MRI methods to define colonic function in health and constipation. Gut, 70(Suppl 1), A32-A33. https://doi.org/10.1136/GUTJNL-2020-BSGCAMPUS.59
  • Stefano MA, Sandy NS, Zagoya C, Duckstein F, Ribeiro AF, Mainz JG, Lomazi EA. Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria. J Cyst Fibros. 2022 May;21(3):497-501. doi: 10.1016/j.jcf.2021.08.021. Epub 2021 Sep 9. No abstract available. PubMed 34511390 ↗
  • Stefano MA, Poderoso RE, Mainz JG, Ribeiro JD, Ribeiro AF, Lomazi EA. Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies. J Pediatr (Rio J). 2020 Nov-Dec;96(6):686-692. doi: 10.1016/j.jped.2020.03.004. Epub 2020 May 8. PubMed 32389617 ↗
  • Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics. 1986 Sep;78(3):473-9. PubMed 3748682 ↗
  • McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, Hao S, Jafri A, Drumm ML, Boron WF, Stern RC, McBennett K, Hodges CA. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G868-G878. doi: 10.1152/ajpgi.00261.2017. Epub 2018 Aug 17. PubMed 30118317 ↗
  • Marciani L, Wright J, Foley S, Hoad CL, Totman JJ, Bush D, Hartley C, Armstrong A, Manby P, Blackshaw E, Perkins AC, Gowland PA, Spiller RC. Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2010 Sep;32(5):655-63. doi: 10.1111/j.1365-2036.2010.04395.x. PubMed 20626735 ↗
  • Marciani L, Garsed KC, Hoad CL, Fields A, Fordham I, Pritchard SE, Placidi E, Murray K, Chaddock G, Costigan C, Lam C, Jalanka-Tuovinen J, De Vos WM, Gowland PA, Spiller RC. Stimulation of colonic motility by oral PEG electrolyte bowel preparation assessed by MRI: comparison of split vs single dose. Neurogastroenterol Motil. 2014 Oct;26(10):1426-36. doi: 10.1111/nmo.12403. Epub 2014 Jul 24. PubMed 25060551 ↗
  • Luo M, Liu Y, Nikolovska K, Riederer B, Patrucco E, Hofmann F, Seidler U. cGMP-dependent kinase 2, Na+/H+ exchanger NHE3, and PDZ-adaptor NHERF2 co-assemble in apical membrane microdomains. Acta Physiol (Oxf). 2024 Apr;240(4):e14125. doi: 10.1111/apha.14125. Epub 2024 Mar 27. PubMed 38533975 ↗
  • Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, Macedo P, Perrin F, Whelan K, Elston C. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J. 2019 Aug;7(7):881-888. doi: 10.1177/2050640619841545. PubMed 31428412 ↗
  • Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I. Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain. Front Mol Neurosci. 2014 Apr 16;7:31. doi: 10.3389/fnmol.2014.00031. eCollection 2014. PubMed 24795564 ↗
  • Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011 Feb;60(2):209-18. doi: 10.1136/gut.2010.227132. PubMed 21205879 ↗
  • Dellschaft N, Murray K, Ren Y, Marciani L, Gowland P, Spiller R, Hoad C. Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function. Neurogastroenterol Motil. 2025 Apr;37(4):e14999. doi: 10.1111/nmo.14999. Epub 2025 Jan 10. PubMed 39789944 ↗
  • Dellschaft N, Hoad C, Marciani L, Gowland P, Spiller R. Small bowel water content assessed by MRI in health and disease: a collation of single-centre studies. Aliment Pharmacol Ther. 2022 Feb;55(3):327-338. doi: 10.1111/apt.16673. Epub 2021 Oct 30. PubMed 34716925 ↗
  • De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013 Sep 1;3(9):a009753. doi: 10.1101/cshperspect.a009753. PubMed 23788646 ↗
  • Corsetti M, Tack J. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterol J. 2013 Feb;1(1):7-20. doi: 10.1177/2050640612474446. PubMed 24917937 ↗
  • Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22. PubMed 23090647 ↗
  • Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, Pierce CM, Solinga RM, Tobin JV, Mahajan-Miklos S, Cohen MB, Kurtz CB, Currie MG. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010 May 8;86(19-20):760-5. doi: 10.1016/j.lfs.2010.03.015. Epub 2010 Mar 20. PubMed 20307554 ↗
  • Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014 Apr;26(4):499-509. doi: 10.1111/nmo.12292. Epub 2013 Dec 18. PubMed 24351035 ↗
  • Aliyu A, Dellschaft N, Hoad C, Williams H, Gaudoin E, Sulaiman S, Crooks C, Gowland P, Aran A, Lange R, Bois De Fer B, Corsetti M, Marciani L, Spiller R. Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation. Clin Pharmacol Ther. 2025 May;117(5):1284-1291. doi: 10.1002/cpt.3532. Epub 2024 Dec 16. PubMed 39679695 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.

Of 62 phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
May 6, 2026
StartActual
Mar 9, 2026
Primary completionEst.
Aug 2026
CompletionEst.
Oct 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569419
Responsible party
Robin Spiller (Professor Robin Spiller, University of Nottingham) — Principal investigator
First posted
May 6, 2026
Start date
Mar 9, 2026
Primary completion
Aug 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
May 6, 2026

Study contacts

Josh Thorley, PhD
Contact
josh.thorley@nottingham.ac.uk
07342646598

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linaclotide

Start the discussion